Novartis AG
New York Stock Exchange•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Dr. Vasant Narasimhan M.D.
- Full Time Employees
- 75,883
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- Lichtstrasse 35 Basel Switzerland 4056
- IPO Date
- Nov 7, 1996
- CIK
- 0001114448
- Website
- novartis.com
- Similar Companies
- Business
- Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Company News
Novartis Fabhalta® shows statistically significant and clinically meaningful improvements in hemoglobin in new population of patients with PNH
Top Cancer Stocks to Supercharge Your 2025 Portfolio
Why Novartis (NVS) is a Top Momentum Stock for the Long-Term
Novartis (NVS) Could Be a Great Choice
2 Dividend Growth Stocks to Buy and Hold Forever
Novartis' Pluvicto shown to slow prostate cancer in earlier setting
Novartis's Cancer Treatment Pluvicto Shows Positive Results in Trial
Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
Buy These 5 Low-Leverage Stocks Amid Volatile Market Sentiment
Novartis announces commencement of tender offer to acquire Regulus Therapeutics
Are You Looking for a High-Growth Dividend Stock?
If I Could Only Buy 2 Dividend Stocks Right Now (May 2025 Edition)
Here's Why Novartis (NVS) is a Strong Value Stock
Novartis (NVS) Upgraded to Buy: What Does It Mean for the Stock?
Should Value Investors Buy Novartis (NVS) Stock?
New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline
Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
Novartis to keep making malaria drugs if orders dry up amid aid cuts
Here's Why Novartis (NVS) is a Strong Momentum Stock